A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis (ADorable-2)
Atopic Dermatitis, Eczema
About this trial
This is an interventional treatment trial for Atopic Dermatitis
Eligibility Criteria
Inclusion Criteria: Received treatment in Study KGBI and have adequately completed the study treatments and last visit of study KGBI. For female participants of childbearing potential, highly effective contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies Exclusion Criteria: Developed an serious adverse events (SAE) during their participation in parent study KGBI deemed related to lebrikizumab, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with lebrikizumab may present an unreasonable risk for the participant. Developed an AE during their participation in the study KGBI that was deemed related to lebrikizumab and led to study treatment discontinuation, which in the opinion of the investigator or of the medical monitor could indicate that continued treatment with lebrikizumab may present an unreasonable risk for the participant. Met the criteria for permanent study intervention discontinuation in study KGBI, if deemed related to lebrikizumab or led to investigator- or sponsor-initiated withdrawal of participant from the study (for example, noncompliance, inability to complete study assessments, etc.) Note: If study KGBI is still blinded at the time of rollover to study KGBJ, conditions deemed related to the study treatment will be considered related to lebrikizumab. Are pregnant or breastfeeding or are planning to become pregnant or breastfeed during the study.
Sites / Locations
- Clinical Research Center of AlabamaRecruiting
- Arkansas Research TrialsRecruiting
- First OC DermatologyRecruiting
- Antelope Valley Clinical TrialsRecruiting
- Dermatology Research AssociatesRecruiting
- Integrative Skin Science and Research - Location 2Recruiting
- UConn HealthRecruiting
- Solutions Through Advanced ResearchRecruiting
- ForCare Clinical ResearchRecruiting
- Treasure Valley Medical ResearchRecruiting
- Northwestern University
- Allergy and Asthma SpecialistRecruiting
- Massachusetts General Hospital
- Oakland Hills DermatologyRecruiting
- Great Lakes Research Group, Inc.Recruiting
- The Derm Institute of West MichiganRecruiting
- Respiratory Medicine Research Institute of Michigan, PLCRecruiting
- Wright State PhysiciansRecruiting
- The Pennsylvania Centre for Dermatology, LLCRecruiting
- Medical University of South CarolinaRecruiting
- The University of Texas Health Science Center at Houston
- Texas Dermatology and Laser SpecialistsRecruiting
- Medical College of Wisconsin
- Instituto de Neumonología Y DermatologíaRecruiting
- Psoriahue
- Centro de Investigaciones Metabólicas (CINME)Recruiting
- Fundacion Cidea
- CONEXA Investigacion Clinica S.A.Recruiting
- Fundación RespirarRecruiting
- Sydney Children's Hospital
- The Children's Hospital at Westmead
- Cornerstone Dermatology
- Veracity Clinical Research Pty LtdRecruiting
- Hospital de Clinicas de Porto Alegre
- Centro de Pesquisa Sao Lucas
- Dermatology Research Institute
- Alberta Dermasurgery Centre
- DermEdge Research
- Hôpitaux Drôme Nord - RomansRecruiting
- Centre Hospitalier Universitaire de Nantes - L' Hopital l'hôtel-DieuRecruiting
- CHU de Toulouse - Hopital LarreyRecruiting
- Hôpital Saint Vincent-de-Paul
- Rosenpark Research GmbH
- Fachklinik Bad BentheimRecruiting
- Universitätsklinikum Münster
- Universitaetsklinikum Carl Gustav Carus Dresden
- Fujita Health UniversityRecruiting
- Fukuyama City HospitalRecruiting
- Asahikawa Medical College HospitalRecruiting
- National Hospital Organization Sagamihara National HospitalRecruiting
- Ina Central HospitalRecruiting
- Osaka Habikino Medical CenterRecruiting
- Kume ClinicRecruiting
- Enomoto ClinicRecruiting
- Sugamo Sengoku DermatologyRecruiting
- Hiroshima University HospitalRecruiting
- University Hospital,Kyoto Prefectural University of MedicineRecruiting
- Okayama City General Medical Center Okayama City HospitalRecruiting
- Hospital de Jesús NazarenoRecruiting
- Trials in Medicine
- Hospital Infantil de Mexico Federico Gomez
- PanAmerican Clinical Research - CuernavacaRecruiting
- Centro de Dermatologia de Monterrey
- Eukarya PharmaSiteRecruiting
- Scientia Investigacion Clinica S.C.
- Arké SMO S.A de C.VRecruiting
- Centrum Medyczne Evimed
- Diamond Clinic
- Centrum Badan Klinicznych PI-House sp. z o.o.
- DERMED Centrum Medyczne Sp. z o.o.
- Hospital Sant Joan de Déu
- Hospital Universitario de Gran Canaria Doctor Negrín
- Hospital Universitario Quironsalud MadridRecruiting
- Clinica Universidad de NavarraRecruiting
- CHOP-Centro De Especialidades De MollabaoRecruiting
- Hospital de ManisesRecruiting
- Hospital Infantil Universitario Niño Jesús
- Hospital Universitario 12 de OctubreRecruiting
- Hospital Universitario La Paz
- Chang Gung Memorial Hospital at KaohsiungRecruiting
- Chung Shan Medical University HospitalRecruiting
- Taipei Veterans General HospitalRecruiting
- National Taiwan University Hospital - Hsinchu branchRecruiting
- National Taiwan University HospitalRecruiting
- Chang Gung Medical Foundation-Linkou BranchRecruiting
Arms of the Study
Arm 1
Experimental
Lebrikizumab + Placebo
Lebrikizumab will be given subcutaneously (SC). Placebo will be administered to maintain the blind of parent study J2T-MC-KGBI.